Psychometric attributes of the rating scale for gait evaluation in Parkinson's disease

Serrano‐Dueñas, Marcos; Calero, Belén; Serrano, Soledad; Serrano, Maite; Coronel, Paulina

doi:10.1002/mds.23152

Cited by 9 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No floor or ceiling effects were found . Internal consistency of the total scale is high; item‐total correlations of separate items ranged from 0.39 to 0.84.…”

Section: Resultsmentioning

confidence: 78%

“…The developers of the Rating Scale for Gait Evaluation (RSGE) recommend using version 2.1), which contains 21 items grouped in 4 subscales (functional ability, long‐term complications, socioeconomic conditions and examination). The scale has been used in at least 5 PD studies . It is administered by a clinician and available in Spanish and English.…”

Section: Resultsmentioning

confidence: 99%

“…Interrater reliability of items (kappa) ranged from 0.54 to 1.00 . Construct validity is supported by high correlations of the total scale with other scales (eg, Barthel Index, UPDRS) and timed tests . Four factors were identified; they did not fully support the prespecified subscales, but were retained for clinical reasons.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations

Bloem¹,

et al. 2016

View full text Add to dashboard Cite

We identified several questionnaires that adequately assess freezing of gait and balance confidence in PD and a number of useful clinical tests. However, most clinical rating scales for gait, balance, and posture perform suboptimally or have been evaluated insufficiently. No instrument comprehensively and separately evaluates all relevant PD-specific gait characteristics with good clinimetric properties, and none provides separate balance and gait scores with adequate content validity for PD. We therefore recommend the development of such a PD-specific, easily administered, comprehensive gait and balance scale that separately assesses all relevant constructs. © 2016 International Parkinson and Movement Disorder Society.

show abstract

“…No floor or ceiling effects were found . Internal consistency of the total scale is high; item‐total correlations of separate items ranged from 0.39 to 0.84.…”

Section: Resultsmentioning

confidence: 78%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations

Bloem¹,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Previous studies found that CISI-PD explains 92% of the CGIS variance and as a whole, correlated at higher level than other global measures with a diversity of scales assessing a diversity of PD-related manifestations and consequences. 9,10,17,18 …”

Section: Discussionmentioning

confidence: 99%

Analysis of four scales for global severity evaluation in Parkinson’s disease

Martinez‐Martín

Rojo-Abuín

Rodríguez-Violante

et al. 2016

npj Parkinson's Disease

Self Cite

View full text Add to dashboard Cite

Global evaluations of Parkinson’s disease (PD) severity are available, but their concordance and accuracy have not been previously tested. The present international, cross-sectional study was aimed at determining the agreement level among four global scales for PD (Hoehn and Yahr, HY; Clinical Global Impression of Severity, CGIS; Clinical Impression of Severity Index, CISI-PD; and Patient Global Impression of Severity, PGIS) and identifying which of them better correlates with itemized PD assessments. Assessments included additional scales for evaluation of the movement impairment, disability, affective disorders, and quality of life. Spearman correlation coefficients, weighted and generalized kappa, and Kendall’s concordance coefficient were used. Four hundred thirty three PD patients, 66% in HY stages 2 or 3, mean disease duration 8.8 years, were analyzed. Correlation between the global scales ranged from 0.60 (HY with PGIS) to 0.91 (CGIS with CISI-PD). Kendall’s coefficient of concordance resulted 0.76 (P<0.0001). HY and CISI-PD showed the highest association with age, disease duration, and levodopa-equivalent daily dose, and CISI-PD with measures of PD manifestations, disability, and quality of life. PGIS and CISI-PD correlated similarly with anxiety and depression scores. The lowest agreement in classifying patients as mild, moderate, or severe was observed between PGIS and HY or CISI-PD (58%) and the highest between CGIS and CISI-PD (84.3%). The four PD global severity scales agree moderately to strongly among them; clinician-based ratings estimate PD severity, as established by other measures, better than PGIS; and the CISI-PD showed the highest association with measures of impairment, disability, and quality of life.

show abstract

“…As cognitive symptoms in PD clearly differ from AD symptoms, it was more and more realised that AD-related assessment tools have relevant flaws in determining cognitive dysfunction in PD, and effort has been put into the development of sensitive and reliable PD-relevant measurement tools. One of the most promising tools is the “Scales for outcomes in Parkinson’s disease-cognition (SCOPA-COG)” having advantages as compared to the MMSE, the most important having a greater discriminative capacity (Serrano-Duenas et al 2010); however, longitudinal studies are not yet available.…”

Section: Clinical Biomarker Candidatesmentioning

confidence: 99%

Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics

et al. 2011

View full text Add to dashboard Cite

Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.

show abstract

Psychometric attributes of the rating scale for gait evaluation in Parkinson's disease

Abstract: Metric attributes of the RSGE-PD-V2.0 in this sample of study resulted in has sufficient and suitable satisfactory. We, therefore, believe that RSGE-PD-V2.0 is easy and a useful and recommendable specific tool for measuring gait disease in PD patients.

Cited by 9 publications

References 35 publications

Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations

Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations

Analysis of four scales for global severity evaluation in Parkinson’s disease

Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics

Contact Info

Product

Resources

About